$0.91 EPS Expected for Mylan (MYL) This Quarter

Cornelia Mascio
Giugno 1, 2017

Three analysts have provided estimates for Mylan's earnings, with estimates ranging from $0.88 to $0.95. The company is expected to report its next quarterly earnings results before the market opens on Wednesday, May 10th. Mylan Inc. had 30 analyst reports since July 27, 2015 according to SRatingsIntel. Covington Capital Mngmt accumulated 5,375 shares or 0.02% of the stock. On average, equities research analysts predict that Mylan will post $5.18 earnings per share for the current year. Vantage Investment Llc has invested 0.01% in Mylan N.V. (NASDAQ:MYL). Mylan had a return on equity of 22.04% and a net margin of 2.50%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion.

A number of research analysts recently weighed in on MYL shares. Gmt Cap invested in 443,400 shares. Standpoint Research initiated it with "Buy" rating and $70.0 target in Wednesday, August 26 report. The rating was maintained by Leerink Swann with "Outperform" on Monday, August 15. The stock has "Buy" rating by Zacks on Monday, August 17. The firm has "Buy" rating by Bryan Garnier & Cie given on Monday, May 23. Royal Bank of Canada's price target points to a potential downside of 7.64% from the company's current price. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. BTIG Research maintained it with "Buy" rating and $85 target in Wednesday, August 19 report. It improved, as 3 investors sold MYL shares while 2 reduced holdings. The stock had a trading volume of 5,166,236 shares. The stock has a 50 day moving average price of $38.13 and a 200 day moving average price of $38.90. The company has market cap of $311.90 million. Mylan has a one year low of $33.60 and a one year high of $50.40.

ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was stolen and reposted in violation of US and global trademark & copyright legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/05/31/first-quadrant-l-p-ca-maintains-stake-in-mylan-myl-updated-updated-updated.html.

In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of the company's stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total value of $1,830,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of large investors have recently modified their holdings of the stock.

Investors sentiment increased to 0.6 in Q4 2016. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,380 shares of the company's stock valued at $1,006,000 after buying an additional 107 shares during the period. Kernodle & Katon Asset Management Group LLC increased its stake in shares of Mylan by 4.7% in the third quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company's stock worth $1,808,088,000 after buying an additional 1,165,852 shares during the period. Conning Inc. increased its stake in shares of Mylan by 1.3% in the first quarter. Company insiders own 0.71% of the company's stock. Ropes Wealth Advisors LLC purchased a new stake in shares of Mylan during the first quarter valued at approximately $136,000. Ls Investment Advisors Llc sold 91,343 shares as the company's stock declined 9.77% while stock markets rallied. Finally, New England Research & Management Inc. increased its stake in shares of Mylan by 3.0% in the first quarter. The rating was upgraded by Citigroup on Friday, November 13 to "Buy". More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: Reuters.com and their article: "Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS" published on May 31, 2017 as well as Law360.com's news article titled: "Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL" with publication date: May 18, 2017. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE